The latest price target for Artelo Biosciences (NASDAQ:ARTL) was reported by D. Boral Capital on December 9, 2024. The analyst firm set a price target for $6.00 expecting ARTL to rise to within 12 months (a possible 457.41% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Artelo Biosciences (NASDAQ:ARTL) was provided by D. Boral Capital, and Artelo Biosciences maintained their buy rating.

There is no last upgrade for Artelo Biosciences

There is no last downgrade for Artelo Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Artelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Artelo Biosciences was filed on December 9, 2024 so you should expect the next rating to be made available sometime around December 9, 2025.

While ratings are subjective and will change, the latest Artelo Biosciences (ARTL) rating was a maintained with a price target of $6.00 to $6.00. The current price Artelo Biosciences (ARTL) is trading at is $1.08, which is out of the analyst’s predicted range.